Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously.

× No keyword cloud information.

18 in total

1. Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD.

Authors: Melvin Berger
Journal: J Clin Immunol Date: 2011-06-04 Impact factor: 8.317

Review 2. Immune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity.

Authors: Luanna Yang; Eveline Y Wu; Teresa K Tarrant
Journal: Curr Allergy Asthma Rep Date: 2016-07 Impact factor: 4.806

Review 3. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors: Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal: J Clin Immunol Date: 2012-06-23 Impact factor: 8.317

Review 4. Intravenous immunoglobulin therapy in rheumatic diseases.

Authors: Jagadeesh Bayry; Vir Singh Negi; Srini V Kaveri
Journal: Nat Rev Rheumatol Date: 2011-05-10 Impact factor: 20.543

5. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.

Authors: Richard L Wasserman; Isaac Melamed; Robert P Nelson; Alan P Knutsen; Mary Beth Fasano; Mark R Stein; Mikhail A Rojavin; Joseph A Church
Journal: Clin Pharmacokinet Date: 2011-06 Impact factor: 6.447

Review 6. Advances in basic and clinical immunology in 2009.

Authors: Javier Chinen; William T Shearer
Journal: J Allergy Clin Immunol Date: 2010-03 Impact factor: 10.793

7. Bioavailability of IgG administered by the subcutaneous route.

Authors: Melvin Berger; Stephen Jolles; Jordan S Orange; John W Sleasman
Journal: J Clin Immunol Date: 2013-03-01 Impact factor: 8.317

Review 8. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.

Authors: Jenny Lingman-Framme; Anders Fasth
Journal: Drugs Date: 2013-08 Impact factor: 9.546

9. Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.

Authors: Kelly L Stoner; Helena Harder; Lesley J Fallowfield; Valerie A Jenkins
Journal: Patient Date: 2014-07-12 Impact factor: 3.883

10. Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.

Authors: Michael C Runken; Joshua M Noone; Christopher M Blanchette; Emily Zacherle; Reuben Howden
Journal: Am Health Drug Benefits Date: 2019-10